Literature DB >> 22439863

Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.

Mei-Jung Lai1, Han-Li Huang, Shiow-Lin Pan, Yi-Min Liu, Chieh-Yu Peng, Hsueh-Yun Lee, Teng-Kuang Yeh, Po-Hsien Huang, Che-Ming Teng, Ching-Shih Chen, Hsun-Yueh Chuang, Jing-Ping Liou.   

Abstract

A series of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles has been identified as a new class of histone deacetylase inhibitors. Compounds 8, 11, 12, 13, and 14 demonstrated stronger antiproliferative activities than 1 (SAHA) with GI(50) values ranging from 0.36 to 1.21 μM against Hep3B, MDA-MB-231, PC-3, and A549 human cancer cell lines. Lead compound 8 showed remarkable HDAC 1, 2, and 6 isoenzymes inhibitory activities with IC(50) values of 12.3, 4.0, 1.0 nM, respectively, which are comparable to 1. In in vivo efficacy evaluation against lung A549 xenograft model, 8 displayed better antitumor activity than compound 1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22439863      PMCID: PMC4201585          DOI: 10.1021/jm300197a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

Review 1.  Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.

Authors:  Cliona Grant; Fahd Rahman; Richard Piekarz; Cody Peer; Robin Frye; Robert W Robey; Erin R Gardner; William D Figg; Susan E Bates
Journal:  Expert Rev Anticancer Ther       Date:  2010-07       Impact factor: 4.512

Review 2.  Developing histone deacetylase inhibitors as anti-cancer therapeutics.

Authors:  B Venugopal; T R J Evans
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 3.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

4.  Synthesis and biological evaluation of 1-(4'-Indolyl and 6'-Quinolinyl) indoles as a new class of potent anticancer agents.

Authors:  Mei-Jung Lai; Jang-Yang Chang; Hsueh-Yun Lee; Ching-Chuan Kuo; Mei-Hsiang Lin; Hsing-Pang Hsieh; Chi-Yen Chang; Jian-Sung Wu; Su-Ying Wu; Kuang-Shing Shey; Jing-Ping Liou
Journal:  Eur J Med Chem       Date:  2011-05-20       Impact factor: 6.514

5.  Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors.

Authors:  Jing-Ping Liou; Zi-Yi Wu; Ching-Chuan Kuo; Chi-Yen Chang; Pei-Yi Lu; Chi-Ming Chen; Hsing-Pang Hsieh; Jang-Yang Chang
Journal:  J Med Chem       Date:  2008-06-28       Impact factor: 7.446

6.  Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.

Authors:  Christian A Olsen; M Reza Ghadiri
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  4- and 5-aroylindoles as novel classes of potent antitubulin agents.

Authors:  Jing-Ping Liou; Chang-Ying Wu; Hsing-Pang Hsieh; Chi-Yen Chang; Chi-Ming Chen; Ching-Chuan Kuo; Jang-Yang Chang
Journal:  J Med Chem       Date:  2007-08-08       Impact factor: 7.446

8.  2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.

Authors:  Siavosh Mahboobi; Andreas Sellmer; Heymo Höcher; Christian Garhammer; Herwig Pongratz; Thomas Maier; Thomas Ciossek; Thomas Beckers
Journal:  J Med Chem       Date:  2007-08-11       Impact factor: 7.446

9.  YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway.

Authors:  S Y Wu; S L Pan; T H Chen; C H Liao; D Y Huang; J H Guh; Y L Chang; S C Kuo; F Y Lee; C M Teng
Journal:  Br J Pharmacol       Date:  2008-07-21       Impact factor: 8.739

10.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

Authors:  Jane A Plumb; Paul W Finn; Robert J Williams; Morwenna J Bandara; M Rosario Romero; Claire J Watkins; Nicholas B La Thangue; Robert Brown
Journal:  Mol Cancer Ther       Date:  2003-08       Impact factor: 6.261

View more
  11 in total

1.  Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents.

Authors:  Dong-Jin Hwang; Jin Wang; Wei Li; Duane D Miller
Journal:  ACS Med Chem Lett       Date:  2015-08-06       Impact factor: 4.345

2.  Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with Indole-Containing Cap Group.

Authors:  Yingjie Zhang; Penghui Yang; C James Chou; Chunxi Liu; Xuejian Wang; Wenfang Xu
Journal:  ACS Med Chem Lett       Date:  2013-01-08       Impact factor: 4.345

3.  Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors.

Authors:  Yu Zhao; Chin-Ho Chen; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Eur J Med Chem       Date:  2021-02-14       Impact factor: 6.514

4.  Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays.

Authors:  Zainab Noor; Noreen Afzal; Sajid Rashid
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

5.  Human histone deacetylase 6 shows strong preference for tubulin dimers over assembled microtubules.

Authors:  Lubica Skultetyova; Kseniya Ustinova; Zsofia Kutil; Zora Novakova; Jiri Pavlicek; Jana Mikesova; Dalibor Trapl; Petra Baranova; Barbora Havlinova; Martin Hubalek; Zdenek Lansky; Cyril Barinka
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

6.  Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.

Authors:  Min-Wu Chao; Li-Hsun Chang; Huang-Ju Tu; Chao-Di Chang; Mei-Jung Lai; Yi-Ying Chen; Jing-Ping Liou; Che-Ming Teng; Shiow-Lin Pan
Journal:  Clin Epigenetics       Date:  2019-05-29       Impact factor: 6.551

7.  A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression.

Authors:  Chih-Ya Wang; Jing-Ping Liou; An-Chi Tsai; Mei-Jung Lai; Yi-Min Liu; Hsueh-Yun Lee; Jing-Chi Wang; Shiow-Lin Pan; Che-Ming Teng
Journal:  Oncotarget       Date:  2014-10-30

8.  Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.

Authors:  Mei-Chuan Chen; Hui-Hsuan Huang; Chin-Yu Lai; Yi-Jyun Lin; Jing-Ping Liou; Mei-Jung Lai; Yu-Hsuan Li; Che-Ming Teng; Chia-Ron Yang
Journal:  Oncotarget       Date:  2016-01-05

9.  Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors.

Authors:  Lanlan Zang; Shukkoor M Kondengaden; Qing Zhang; Xiaobo Li; Dilep K Sigalapalli; Shameer M Kondengadan; Kenneth Huang; Keqin Kathy Li; Shanshan Li; Zhongying Xiao; Liuqing Wen; Hailiang Zhu; Bathini N Babu; Lijuan Wang; Fengyuan Che; Peng George Wang
Journal:  Oncotarget       Date:  2017-06-28

Review 10.  Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents.

Authors:  Jyothi Dhuguru; Rachid Skouta
Journal:  Molecules       Date:  2020-04-01       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.